Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) will announce its first quarter 2022 financial results on May 5, 2022, before U.S. market opening. A conference call will follow at 8:00 am E.T. to discuss results and company updates. Provention Bio focuses on developing therapies for immune-mediated diseases, including type 1 diabetes and lupus. Investors can access the call at 1-888-347-7861 (domestic) or 1-412-902-4247 (international), or via an audio webcast on the company's website. An archived version will be available shortly after the call.

RED BANK, N.J., April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a company update.

To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call.

About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease, and lupus. Visit www.proventionbio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:
Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contact:
Robert Doody, VP of Investor Relations
rdoody@proventionbio.com 
484-639-7235

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-report-first-quarter-2022-financial-results-on-may-5-2022-301534241.html

SOURCE Provention Bio, Inc.

FAQ

When will Provention Bio report its first quarter 2022 financial results?

Provention Bio will report its first quarter 2022 financial results on May 5, 2022, before U.S. market opening.

What time is the conference call about Provention Bio's financial results?

The conference call will take place at 8:00 am E.T. on May 5, 2022.

How can I access the conference call for Provention Bio?

You can access the call by dialing 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time.

What is the focus of Provention Bio's business?

Provention Bio is focused on developing therapies to intercept and prevent immune-mediated diseases.